Clinical Trial: Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07690891) titled 'Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia' on July 01.

Brief Summary: This is a single-arm, open-label Phase 2 study designed to evaluate the treatment outcomes of nemtabrutinib-venetoclax-obinutuzumab as a frontline management for chronic lymphocytic leukemia (CLL).

Study Start Date: Oct. 01, 2026

Study Type: INTERVENTIONAL

Condition: Chronic Lymphocytic Leukemia

Intervention: DRUG: Nemtabrutinib

45 mg daily for 15 28-day cycles.

DRUG: Venetoclax

Cycle 4, Days 1-7: 20 mg; Cycle 4, Days 8-14: 50 mg; Cycle 4, Days 15-21: 100 mg; Cycle 4, Days 22-28: 200 mg; Cycle 5-15: 400 mg...